Loading stock data…
LQDA
$38.14-1.07 (-2.73%)
Market ClosedLast close May 1
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Liquidia Corporation in the Healthcare sector is trading at $38.14. The stock is currently 18% below its 52-week high of $46.67, remaining 23.6% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why LQDA maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$38.14
Potential Upside
5%
Whystock Fair Value$40.05
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$50.67+32.8%
Range$19.00 – $67.00
Fundamentals
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.27B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.46
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-102.90%
Volume
Today's trading volume
804,351
Recent News
Does Tom Steyer’s YUTREPIA Endorsement Reframe the Bull Case for Liquidia (LQDA)?
Recently, Liquidia Corporation was highlighted as the top pick on billionaire Tom Steyer’s list of stocks with major upside potential, amid rapid real‑world uptake of its dry‑powder treprostinil therapy YUTREPIA for pulmonary hypertension and management commentary outlining a path toward a US$1.00 billion franchise by 2027. An interesting angle for investors is that this outside endorsement aligns with management’s own growth ambitions, underscoring how confidence in YUTREPIA’s commercial...
Liquidia Corporation (LQDA): Billionaire Tom Steyer Admires This Pharma Stock
We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Liquidia Corporation (NASDAQ:LQDA) ranks 1st on this list. Liquidia Corporation (NASDAQ:LQDA) first appeared in the 13F portfolio of Farallon Capital in the second quarter of 2020. Back then, this position comprised 1.8 million shares. The fund sold off this stake before the […]
This Drug Stock Nears A Buy Point, With Profit Set To Explode
This drug stock is testing a moving average in a base. This biopharma name has a patented technology to administer its drug.
Liquidia Corp (LQDA) Surged Following the Successful Acceptance of Its YUTREPIA Drug
Laughing Water Capital, an investment management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Class A investment in Laughing Water Capital returned approximately -4.5% net of all fees and expenses in the first quarter of 2026. The SP500TR and R2000 returned -4.3% and 0.9% respectively, during the […]
Liquidia's (LQDA) CEO Sells 53,000 Shares for $2.1 Million
Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its core market.